Key Takeaway: Eloxx Pharmaceuticals has announced significant updates regarding its clinical pipeline and financing. The company has dosed the first two subjects in a Phase 1 trial for ZKN-013. Additionally, positive feedback from the FDA has provided a pathway for an IND submission for a Phase 2 trial of ELX-02 in NMAS patients. Eloxx has also secured $3.2 million in financing to support its clinical programs.
Price reaction · baseline $7.4547 (2024-07-10 close) · hit pre-market · clean, no other ELOX news in the window
day 0 close
+10.7%
day 1 · peak
+18%
day 3
+3.3%
Market Sentiment Analysis
POSITIVE FACTORS
First two subjects dosed in Phase 1 trial of ZKN-013.
Positive FDA feedback supports IND submission for ELX-02.
Secured $3.2 million in financing to advance programs.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+144%
120-day peak, hindsight
Typical move
20.6%
average across 3 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Full Press Release Details
First two subjects dosed in Phase 1 clinical trial of ZKN-013. Positive written FDA feedback from pre-IND meeting provides pathway to IND submission for a US Phase 2 trial of ELX-02 in NMAS patients. Eloxx secures $3.2 million in additional financing to advance clinical programs.
The post Eloxx Pharmaceuticals Provides Pipeline and Financing Updates appeared first on Eloxx Pharmaceuticals .
Frequently Asked Questions
What is the latest update on ZKN-013?
The first two subjects have been dosed in the Phase 1 clinical trial of ZKN-013.
What feedback did Eloxx receive from the FDA?
Eloxx received positive written feedback from the FDA, supporting an IND submission for ELX-02.
How much financing has Eloxx secured?
Eloxx has secured $3.2 million in additional financing for its clinical programs.
Biotech snapshot
Cash runway
$62M liquidity · $2M/mo burn
~37 mo
Minimal dilution risk
Catalyst track record
+144%
best trade around ELOX's most recent catalyst
Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for ELOX.